[2026 Parliamentary Audit] Choline Alfoscerate Clawback Rate at 20%... NHIS: "Will Consult with Health Ministry"
NHIS Sought 100% Clawback, but Agreed to 20% After Negotiations
Rep. Jeon Jongdeok Calls for End to Secrecy Over Clawback Terms
NHIS President Kang Cheonghee: "I Agree in Principle, but There Are Legal Issues... Will Consult with the Health Ministry"
Concerns were raised during a parliamentary audit over clawback agreements the National Health Insurance Service (NHIS) signed with pharmaceutical companies in preparation for the failure of a clinical re-evaluation of choline alfoscerate products. The NHIS initially sought to recover the full amount of insurance claims, but the final clawback rate was set at 20%. Because this means 80% of the reimbursed amount would not be recovered even if the products fail to demonstrate efficacy, concerns were raised about financial leakage from the National Health Insurance Fund.
Progressive Party lawmaker Jeon Jongdeok questioned the appropriateness of the clawback agreement for choline alfoscerate during a parliamentary audit of the NHIS and the Health Insurance Review and Assessment Service at the National Assembly Health and Welfare Committee on October 16. According to Jeon, when the Ministry of Health and Welfare ordered clawback negotiations in December 2020, the NHIS proposed recovering 100% of the claimed amount, while pharmaceutical companies argued for a rate of around 10%. The NHIS later lowered its demand to 50%, but negotiations broke down. After further negotiations, the clawback rate was set at 20%.
Progressive Party lawmaker Jeon Jongdeok questions National Health Insurance Service President Kang Cheong-hee during a parliamentary audit of the National Health Insurance Service and the Health Insurance Review and Assessment Service before the National Assembly Health and Welfare Committee on the 16th. Screenshot from the National Assembly Internet Live Broadcasting System.
View original imageCholine alfoscerate is an ingredient that has been prescribed to improve brain function. In a clinical re-evaluation conducted this year for its indication for mild cognitive impairment, it failed to meet the primary endpoint in the main analysis. The clawback process is expected to begin in earnest once the Ministry of Food and Drug Safety determines whether to maintain the indication.
Jeon pointed out that pharmaceutical companies had responded to each stage of the reimbursement management process with lawsuits. It took about five years for the selective reimbursement decided in 2020 to be implemented because of lawsuits and injunctions suspending its enforcement. Pharmaceutical companies sued to overturn the order to negotiate clawbacks and, after the agreements were signed, also filed lawsuits seeking to invalidate them. Jeon criticized the companies for now seeking to maintain approval through post hoc analyses despite failing the clinical re-evaluation.
Jeon asked NHIS President Kang Cheonghee, who was the executive director in charge of reimbursement at the time, why the NHIS initially sought to recover 100% of the amount. Kang replied that the intent was to recover the full amount if the product was found to be ineffective. Jeon pressed him on the basis for reducing the clawback rate to 20%, given that pharmaceutical companies are responsible for demonstrating efficacy.
The limited period covered by the clawback was also raised. The current agreement covers prescriptions issued after approval of the clinical re-evaluation, meaning reimbursements paid before that point cannot be recovered. Jeon expressed concern that the clawback rate for choline alfoscerate could become a benchmark for negotiations over clawbacks for other drugs.
The NHIS has signed conditional clawback agreements linked to clinical re-evaluations for six ingredients, including choline alfoscerate. Of these, streptokinase-streptodornase and sulglycotide were removed from reimbursement after failing to demonstrate efficacy. Clawbacks for streptokinase-streptodornase were completed in September 2024, while clawbacks for sulglycotide are scheduled for this month.
Jeon also took issue with the practice of keeping clawback agreement terms confidential. Citing mutual confidentiality agreements, the NHIS did not provide the lawmaker's office with the specific terms it had requested. However, details including the 20% clawback rate for choline alfoscerate, the 22.5% rate for streptokinase-streptodornase, a one-year clawback period, and a clawback amount of KRW 2.87 billion had already been reported in the media. Jeon said it was difficult to understand why information known to the industry and the media was being kept secret only from the National Assembly, stressing that the public has a right to know how much of its insurance premiums is being recovered.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jeon called for the system to be changed so that the terms of clawback agreements are disclosed as a matter of principle, the clawback period starts from the announcement of the re-evaluation, and the full amount is recovered for drugs that fail to demonstrate efficacy. Kang replied, "I agree in principle, but there are legal issues," adding, "I will consult with the Ministry of Health and Welfare and address the matter."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.